Story thread · 2 reports / 1 sources
Belite Bio outlines February 12, 2027 PDUFA date for Tinlarebant in Stargardt disease following FDA priority review acceptance
seekingalpha.com · 2h
First report: Belite Bio wins FDA priority review for lead candidate — seekingalpha.com, 1d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.